DNA vaccine candidate by Zydus Cadila, protein subunit vaccine candidate by BioE, mRNA disease candidate by Gennova, and also only dose intranasal vaccine candidate by Bharat Biotech are at advanced stages of clinical trials,” said Department of Biotechnology Secretary Renu Swarup on April 21.

Efforts have been summed up for gigantic production of COVID-19 vaccines and also make sure they are available within the shortest feasible moment, the DBT Secretary said, stressing that India now has a promising form of four-five vaccine applicants, whereas three’ve been already approved for emergency usage.

“you will find 3 vaccines from India, that may have now been approved for Agency Use Authorisation -‘Covishield’ by Serum Institute of India (SII),’Covaxin‘ by Bharat Biotech International Ltd (BBIL) and the Russian embryo,’Sputnik-V’. Besides these, There’s a promising pipeline of four-five applicants in advanced clinical stages of growth,” stated Swarup

The Centre has given Rs 1,500 crore into Bharat Biotech for commercial production of Covaxin.

Incidentally, the business has also written into the India’s medication regulator searching expansion of this shelf life of its own indigenously developed COVID-19 vaccine Covaxin out of six to 24 weeks.

(With inputs from PTI)